* Accolade Inc ACCD.OQ reported a quarterly adjusted loss
of 10
cents per share for the quarter ended in February, higher than
the same quarter last year, when the company reported EPS of -42
cents. The mean expectation of sixteen analysts for the quarter
was for a loss of 7 cents per share. Wall Street expected
results to range from -16 cents to 10 cents per share.
* Revenue rose 26.1% to $124.83 million from a year ago;
analysts
expected $123.91 million.
* Accolade Inc's reported EPS for the quarter was a loss
of 10
cents.
* The company reported a quarterly loss of $7.51 million.
* Accolade Inc shares had fallen by 10.3% this quarter and
lost 21.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 8.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"
Wall Street's median 12-month price target for Accolade Inc is
$16.00
This summary was machine generated from LSEG data April 25 at
11:12 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Feb. 29 2024 -0.07 -0.10 Missed
Nov. 30 2023 -0.44 -0.28 Beat
Aug. 31 2023 -0.54 -0.43 Beat
May. 31 2023 -0.62 -0.52 Beat